Search

Displaying results 5071 - 5080 of 10000 in total
  1. Drug

    VLTS-934

    go.drugbank.com/drugs/DB05597
    Investigational

    It was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease). … VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).

  2. Drug

    Cyanocobalamin Co-60

    go.drugbank.com/drugs/DB09387
    ApprovedWithdrawn

    Cyanocobalamin Co-60 was used for the diagnosis of pernicious anemia, but now it is withdrawn from the market in the US for unknown reasons. … Cyanocobalamin Co-60 is an analog of Vitamin B12 labeled with Co60.

  3. Drug

    Bioymifi

    go.drugbank.com/drugs/DB17493
    Experimental

    Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent. … Bioymifi is a small molecule that acts as a tumor necrosis factor-related apoptosis-induced ligand (TRAIL) mimetic.

  4. Drug

    Etamivan

    go.drugbank.com/drugs/DB08989
    ApprovedWithdrawn

    Etamivan (INN) or ethamivan (USAN) is marketed under the name Analepticon. Etamvin is a respiratory stimulant drug similar to nikethamide. It is no longer used in the United States.

  5. Drug

    Depreotide

    go.drugbank.com/drugs/DB11628
    ApprovedWithdrawn

    Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.

  6. Drug

    Hesperidin

    go.drugbank.com/drugs/DB04703
    ApprovedInvestigational

    Hesperidin is a flavan-on glycoside found in citrus fruits.

  7. Drug

    MVA3000

    go.drugbank.com/drugs/DB05040
    Experimental

    MVA3000 is an attenuated smallpox vaccine that is being developed for use in people for whom the traditional smallpox vaccine is contraindicated, such as patients with disorders of the immune system or

  8. Drug

    INM005

    go.drugbank.com/drugs/DB16499
    Investigational

    INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984).

    Synonyms: INM-005 (PURIFIED FAB'2 FRACTION OF EQUINE HYPERIMMUNE SERUM GENERATED FROM ANTIGENIC STIMULATION WITH THE SARS-COV2 RBD PROTEIN)
  9. Drug

    NS-3728

    go.drugbank.com/drugs/DB05835
    Experimental

    NS3728 is an orally active chloride channel blocker for the treatment of cancer.

    Synonyms: N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea
  10. Drug

    BG-777

    go.drugbank.com/drugs/DB05839
    Experimental

    BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.